Your browser doesn't support javascript.
loading
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun, Jong-Mu; Shen, Lin; Shah, Manish A; Enzinger, Peter; Adenis, Antoine; Doi, Toshihiko; Kojima, Takashi; Metges, Jean-Philippe; Li, Zhigang; Kim, Sung-Bae; Cho, Byoung Chul; Mansoor, Wasat; Li, Shau-Hsuan; Sunpaweravong, Patrapim; Maqueda, Maria Alsina; Goekkurt, Eray; Hara, Hiroki; Antunes, Luis; Fountzilas, Christos; Tsuji, Akihito; Oliden, Victor Castro; Liu, Qi; Shah, Sukrut; Bhagia, Pooja; Kato, Ken.
Afiliação
  • Sun JM; Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea. Electronic address: jongmu.sun@skku.edu.
  • Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Shah MA; Weill Cornell Medical College, New York City, NY, USA.
  • Enzinger P; Dana Farber Cancer Institute, Boston, MA, USA.
  • Adenis A; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm, Université Montpellier, ICM, Montpellier, France.
  • Doi T; National Cancer Center Hospital East, Kashiwa, Japan.
  • Kojima T; National Cancer Center Hospital East, Kashiwa, Japan.
  • Metges JP; CHU Brest-Institut de Cancerologie et d'Hematologie ARPEGO Network, Brest, France.
  • Li Z; Section of Oesophageal Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
  • Mansoor W; Christie Hospital NHS Trust, Manchester, UK.
  • Li SH; Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Sunpaweravong P; Prince of Songkla University Hospital, Songkhla, Thailand.
  • Maqueda MA; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Goekkurt E; Hematology Oncology Practice Eppendorf and University Cancer Center Hamburg, Hamburg, Germany.
  • Hara H; Saitama Cancer Center, Saitama, Japan.
  • Antunes L; University Hospital of Santa Maria, Federal University of Santa Maria, and Viver Research Center, Santa Maria, Brazil.
  • Fountzilas C; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Tsuji A; Kagawa University Hospital, Kagawa, Japan.
  • Oliden VC; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
  • Liu Q; Merck, Kenilworth, NJ, USA.
  • Shah S; Merck, Kenilworth, NJ, USA.
  • Bhagia P; Merck, Kenilworth, NJ, USA.
  • Kato K; National Cancer Center Hospital, Tokyo, Japan.
Lancet ; 398(10302): 759-771, 2021 08 28.
Article em En | MEDLINE | ID: mdl-34454674
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Anticorpos Monoclonais Humanizados / Fluoruracila / Antineoplásicos Imunológicos / Carcinoma de Células Escamosas de Cabeça e Pescoço Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Anticorpos Monoclonais Humanizados / Fluoruracila / Antineoplásicos Imunológicos / Carcinoma de Células Escamosas de Cabeça e Pescoço Tipo de estudo: Clinical_trials Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article